Polatuzumab vedotin and Sargramostim Solution for Injection
Determining the interaction of Polatuzumab vedotin and Sargramostim Solution for Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells. MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents. References "Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA. "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA. "Product Information. Stemgen (ancestim)" Amgen, Thousand Oaks, CA. "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA. View all 4 references
Professional:ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.
- "Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA.
- "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA.
- "Product Information. Stemgen (ancestim)" Amgen, Thousand Oaks, CA.
- "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA.
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab Vedotin
Generic Name: sargramostim
Brand name: Leukine
Synonyms: Sargramostim
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Polatuzumab vedotin-Sarilumab
- Polatuzumab vedotin-Sarilumab Prefilled Pens
- Polatuzumab vedotin-Sarilumab Prefilled Syringes
- Polatuzumab vedotin-Sarilumab Subcutaneous
- Polatuzumab vedotin-Sarna Hc Topical application
- Polatuzumab vedotin-Sarnol-HC
- Sargramostim Solution for Injection-Polatuzumab Vedotin-piiq
- Sargramostim Solution for Injection-Polio vaccine, inactivated
- Sargramostim Solution for Injection-Poliovirus Vaccine (Inactivated)
- Sargramostim Solution for Injection-Poliovirus vaccine, inactivated Injection
- Sargramostim Solution for Injection-Polivy
- Sargramostim Solution for Injection-Polmon